Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter ...

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. | The U.S. watchdog is taking ...

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Adding pyrotinib to trastuzumab and docetaxel prolonged progression-free survival in patients with HER2-positive metastatic breast cancer.

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Centiva Capital LP reduced its stake in Novartis AG (NYSE:NVS – Free Report) by 48.1% during the 3rd quarter, HoldingsChannel ...

Although not a game changer for Pfizer, the data could help cushion Ibrance’s losses of market share to Kisqali, a similar ...